Prognostic value of *MLH1* promoter methylation in male patients with esophageal squamous cell carcinoma

DONGPING WU[1*], XIAOYING CHEN[2*], YAN XU[2*], HAIYONG WANG[3],
GUANGMAO YU[3], LUPING JIANG[2], QINGXIAO HONG[2] and SHIWEI DUAN[2]

[1]Department of Medical Oncology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University,
Shaoxing, Zhejiang 312000; [2]Medical Genetics Center, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211;
[3]Thoracic Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University,
Shaoxing, Zhejiang 312000. P.R. China

Abstract. The DNA mismatch repair (MMR) gene MutL homolog 1 (*MLH1*) is critical for the maintenance of genomic integrity. Methylation of the *MLH1* gene promoter was identified as a prognostic marker for numerous types of cancer including glioblastoma, colorectal, ovarian and gastric cancer. The present study aimed to determine whether *MLH1* promoter methylation was associated with survival in male patients with esophageal squamous cell carcinoma (ESCC). Formalin-fixed, paraffin-embedded ESCC tissues were collected from 87 male patients. *MLH1* promoter methylation was assessed using the methylation-specific polymerase chain reaction approach. Kaplan-Meier survival curves and log-rank tests were used to evaluate the association between *MLH1* promoter methylation and overall survival (OS) in patients with ESCC. Cox regression analysis was used to obtain crude and multivariate hazard ratios (HR), and 95% confidence intervals (CI). The present study revealed that *MLH1* promoter methylation was observed in 53/87 (60.9%) of male patients with ESCC. Kaplan-Meier survival analysis demonstrated that *MLH1* promoter hypermethylation was significantly associated with poorer prognosis in patients with ESCC (P=0.048). Multivariate survival analysis revealed that *MLH1* promoter hypermethylation was an independent predictor of poor OS in male patients with ESCC (HR=1.716; 95% CI=1.008-2.921). Therefore, *MLH1* promoter hypermethylation may be a predictor of prognosis in male patients with ESCC.

Introduction

Esophageal cancer (EC) is a lethal disease that presents a global health threat to humans (1) particularly in developing countries, including China (2). A major histological subtype of EC is esophageal squamous cell carcinoma (ESCC) (3). Despite medical and surgical advances, the prognosis for EC remains poor (4).

Esophageal cancer may be caused by various environmental factors, including chronic exposure to nitrosamines, obesity, smoking and alcohol (5). Tobacco and alcohol consumption are the predominant risk factors for ESCC (6,7). In addition, accumulating epidemiological studies indicated an association between obesity and EC (2,8-10).

Encompassing the genetic and environmental aspects of cancer development, epigenetic modification is considered to have a crucial role in the carcinogenesis of EC (11). DNA methylation is as a key mechanism in the inhibition of the expression of tumor suppressor genes (12). Aberrantly methylated genes have previously been identified as prognostic markers in EC (13,14).

DNA mismatch repair (MMR) genes, including MutL homolog (*MLH)1*, *MLH3*, MutS protein homolog *(MSH)2* and *MSH3*, are critical for maintaining genomic integrity (15,16). The loss of MMR function is closely correlated with carcinogenesis (17-20). *MLH1* encodes a protein that has been implicated in the maintenance of genome stability during DNA replication (21-23). A previous study indicated that *MLH1* promoter hypermethylation was able to inactivate gene transcription, inducing defects in the function of the DNA repair system (24). Therefore, *MLH1* contributes to the subsequent development of tumors including ESCC (24,25). *MLH1* promoter methylation is significantly higher in EC tissues, as compared with paired adjacent tissues (15); however, the association between *MLH1* promoter methylation and the prognosis of EC has yet to be elucidated.

In the current study, *MLH1* methylation was investigated in a total of 87 male patients with ESCC, with the aim of

determining the prognostic value of *MLH1* methylation in this disease.

Materials and methods

Tissue samples. In a retrospective study, formalin-fixed paraffin-embedded (FFPE) tissues (4 μm in thickness) from the primary tumors of 87 male patients diagnosed with ESCC were selected from the archive at the Department of Thoracic Surgery, Shaoxing People's Hospital (Shaoxing, China) between October 1998 and June 2007. No preoperative radiotherapy or chemotherapy was administered prior to the collection of FFPE samples. The paraffin-embedded tissue block of ESCC was sliced transversely using Leica RM2245 Semi-Automated Rotary Microtome (Leica Microsystems GmbH, Wetzlar, Germany). All sections were reviewed with minimum of 75% malignant cells. Pathological parameters were defined according to the World Health Organization guidelines and Union for International Cancer Control tumor-node-metastasis classifications (26). Follow-up data was recorded for 70/87 patients until January 2010, and the maximum follow up period was 11 years and 3 months. The overall survival (OS) time was evaluated from the date of primary surgery to patient mortality, or to the date of the final follow-up (27). Information on clinicopathological characteristics was retrieved from the patient medical records and pathological diagnosis. The present study was approved by the Bioethics Committee of Shaoxing People's Hospital and written informed consent was obtained from all participants.

DNA isolation and bisulfite conversion. Genomic DNA was extracted from the tissue samples using the E.Z.N.A® Tissue DNA kit (Omega Bio-Tek, Inc., Norcross, GA, USA) according to the manufacturer's protocol. DNA concentrations were evaluated using the NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, Inc., Wilmington, DE, USA). Bisulfite conversion of genomic DNA was performed using the EZ DNA Methylation-Gold™ kit (Zymo Research Corp., Irvine, CA, USA), which converted only unmethylated cytosine to uracil.

Methylation-specific polymerase chain reaction (MSP). MSP was performed to qualitatively detect the methylation status of *MLH1* (Fig. 1). The total amplification involved a reaction volume of 20 μl, containing 0.5 μl forward and reverse primers, 1.6 μl sodium bisulfate-modified DNA, 10 μl ZymoTaq™ PreMix (Zymo Research Corp.) and 7.4 μl DNase/RNase-free water. The applied MSP primers were as described previously (28), whereas the primer sequences for the *MLH1* methylated (M) alleles were as follows: Forward, 5'-AACGAATTAATAGGAAGAGCGGATAGCG-3' and reverse, 5'-CGTCCCTCCCTAAAACGACTACCC-3'. The primer sequences for *MLH1* unmethylated (U) alleles were forward, 5'-TAAAAATGAATTAATAGGAAGAGTGGA TAGTG-3' and reverse, 5'-AATCTCTTCATCCCTCCCTAA AACA-3'. For PCR, the M and U primer pairs were initially denatured at 95˚C for 10 min, followed by 35 cycles with 30 sec denaturation, 45 sec annealing at 55˚C, and 1 min extension at 72˚C. Following a subsequent 7 min extension at 72˚C, the product was stored at 4˚C. A number of DNA samples were also randomly sequenced to determine a complete bisulfite conversion, using the Applied Biosystems™ 3730 DNA Analyzer (Thermo Fisher Scientific, Inc., Waltham, MA, USA; Fig. 1).

Statistical analysis. Statistical analysis was conducted with SPSS 18.0 software (SPSS Inc., Chicago, IL, USA). The Fisher's exact probability method or χ^2 test was performed to compare the methylation frequencies between the groups. The Kaplan-Meier method was used to estimate the medium OS time for survival analyses. Log-rank tests were used for comparison of the survival curves. Potentially important factors in univariate analyses were then included in multivariate analyses. The Cox proportional hazards models was applied to calculate hazard ratios (HR) and the corresponding 95% confidence intervals (CI). P<0.05 was considered to indicate a statistically significant difference.

Results

Patient characteristics. As presented in Table I, the median survival time of patients with ESCC was 74.0 months, ranging from 1.5-135 months. The mean age of patients with ESCC was 62.63±8.48 years. Of the 87 patients with ESCC, 34 (39.1%) and 53 (60.9%) cases were in the early-stage (I and II) and the advanced-stage (III and IV), respectively. In addition, 43 (49.4%) and 42 (48.3%) patients consumed alcohol and smoked cigarettes, respectively. Patients were classified as being alcohol consumers if they had consumed at least one alcoholic drink in the last 30 days (29). Smoking was classified based upon whether the patient had smoked continuously for >6 months during their lifetime (30).

MLH1 promoter methylation in ESCC tissues. As presented in Table I, *MLH1* promoter methylation was observed in 53/87 (60.92%) ESCC tissue samples. No significant differences were observed in further correlation analyses between *MLH1* methylation and clinical phenotypes (All P>0.05). The evaluated clinical phenotypes were as follows: Age at diagnosis, smoking behavior, history of alcohol consumption and clinicopathological characteristics, including tumor location, histological differentiation, lymph node metastasis, clinical stage, surgical margin status and vascular invasion.

Survival analysis. As presented in Table II, the univariate survival analysis demonstrated that the OS of patients with ESCC was associated with age at the time of surgery (P=0.028), history of alcohol consumption (P=0.015) and vascular invasion (P=0.015). Meanwhile, *MLH1* promoter methylation was significantly associated with poor OS in patients with ESCC (P=0.048; Fig. 2). Following adjustments for these potential confounding factors in a multivariate Cox proportional hazards model, the OS of patients with ESCC was observed to be significantly associated with *MLH1* promoter hypermethylation (HR=1.716; 95% CI=1.008-2.921), age ≤60 years old (HR=0.486, 95%; CI=0.279-0.849), alcohol consumption (HR=1.968; 95% CI=1.157-3.348) and vascular invasion (HR=1.791; 95% CI=1.007-3.185).

Figure 1. Representative results of sequencing validation and methylation-specific polymerase chain reaction. (A) Top row of nucleotides represents the original sequence of the gene, and the second row provides the converted sequences. (B) M and U represent methylated (91 bp) and unmethylated (102 bp) MutL homolog 1 products. *MLH1*, MutL homolog 1; *MLHI*-MF, represents the use of the forward methylated primer for sequencing; *MLHI*-UF, represents the use of the forward unmethylated primer for sequencing.


Figure 2. Kaplan-Meier survival curves comparing the survival (months) of patients with esophageal cancer and methylated or unmethylated *MLH1* promoter regions. *MLH1*, MutL homolog 1; cum, cumulative.

Discussion

In the current study, *MLH1* promoter methylation and OS was investigated in male patients with ESCC. *MLH1* promoter hypermethylation was significantly associated with poor OS in male patients with ESCC. Furthermore, diagnostic age, alcohol consumption and vascular invasion were also independent factors for the OS of patients with ESCC.

DNA mismatch repair is a conserved process that is critical for correcting any generated mismatches that escape proofreading during DNA replication (25). *MLH1* is one of the major genes involved in this process (25). The loss of the MLH1 protein may be detected in ~72% of ESCC tumors,

Table I. Baseline clinical phenotypes and *MLH1* promoter methylation in patients with ESCC.

Variables	N	*MLH1* promoter methylation	*MLH1* promoter unmethylation	P-value
Age at surgery, years				0.810
≤60	37	22	15	
>60	50	31	19	
Tumor location				0.600[a]
Upper	4	2	2	
Middle	39	22	17	
Lower	44	29	15	
Differentiation				0.439[a]
Well differentiated	8	4	4	
Moderately differentiated	46	26	20	
Poorly differentiated	33	23	10	
Lymph node metastasis				0.737
Negative	39	23	16	
Positive	48	30	18	
Disease stage				0.441
I and II	34	19	15	
III and IV	53	34	19	
Smoking history				0.486
Positive	42	24	18	
Negative	45	29	16	
Drinking history				0.335
Positive	43	24	19	
Negative	44	29	15	
Surgical margin				0.616
Negative	72	43	29	
Positive	15	10	5	
Vascular invasion				0.536
Negative	67	42	25	
Positive	20	11	9	

[a]Fisher's exact test, for all other P-values a Chi-square test was performed. *MLH1*, MutL homolog 1; N, number of patients; ESCC, esophageal squamous cell carcinoma.

concordant with *MLH1* promoter hypermethylation, which is correlated with reduced gene expression levels (31,32). *MLH1* promoter hypermethylation has been reported in numerous types of tumors, including colorectal (33), gastric cancer (34) and EC (35). Previous studies have also reported that *MLH1* hypermethylation may be associated with poor prognosis for patients with gastric (22), ovarian (36) and colorectal cancer (37), whilst studies on the prognostic value of *MLH1* methylation in Han Chinese patients with EC or ESCC are scarce. The present study demonstrated that *MLH1* promoter hypermethylation is a prognostic marker of ESCC in Chinese males.

The epidemiology of ESCC demonstrates that there is a high gender bias, evidenced by a gender ratio of 8-9:1 in favor of males (38). In addition, the consumption of alcohol and cigarettes occurs more frequently in males, as compared with in females in China (39,40). Although the present study did not examine whether alcohol and cigarette consumption were risk factors for ESCC, as investigated in previous studies (41,42), the results demonstrated that the consumption of alcohol was significantly associated with poor OS in ESCC. Vascular invasion has previously been significantly correlated with ESCC (43). In the present study, patients with vascular invasion had a significantly shorter survival time, compared with patients without, suggesting a role for vascular invasion in the progression and prognosis of ESCC.

In conclusion, the present study identified *MLH1* promoter methylation as a prognostic marker of ESCC. It was also demonstrated that patients with ESCC significantly benefited from early-stage diagnosis. Alcohol consumption, smoking and vascular invasion may be involved in the progression of ESCC; however, further studies are required to investigate these findings.

Table II. Survival analysis of 87 patients with esophageal cancer with MSP detection of *MLH1* promoter methylation.

Variables	Median OS, (months)	χ^2	Univariate P-value	HR (95% CI)	Multivariate P-value
Age at surgery, years			0.028[a]		0.011[a]
≤60	31.5	4.812		0.486 (0.279-0.849)	
>60	14.0				
Tumor location			0.835		
Upper	31.5	0.360			
Middle	19.0				
Lower	17.0				
Differentiation			0.138		
Well differentiated	50.0	3.965			
Moderately differentiated	21.0				
Poorly differentiated	14.0				
Lymph node metastasis			0.211		
Negative	24.5	1.566			
Positive	14.5				
Disease stage			0.213		
I and II	21.0	1.551			
III and IV	14.5				
Smoking history			0.307		
Positive	17.0	1.042			
Negative	20.0				
Drinking history			0.015[a]		0.013[a]
Positive	13.0	5.880		1.968 (1.157-3.348)	
Negative	22.0				
Surgical margin			0.421		
Negative	19.0	0.647			
Positive	14.5				
Vascular invasion			0.015[a]		0.047[a]
Positive	12.5	5.903		1.791 (1.007-3.185)	
Negative	22.5				
Methylated status of *MLH1* promoter			0.048[a]		0.047[a]
Methylation	16.5	3.902		1.716 (1.008-2.921)	
Unmethylation	27.0				

[a]$P<0.05$. *MHL1*, MutL homolog 1; OS, overall survival; HR, hazard rate; MSP, methylation-specific polymerase chain reaction.

References

1. Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet 381: 400-412, 2013.

2. Zhang Y: Epidemiology of esophageal cancer. World J Gastroenterol 19: 5598-5606, 2013.

3. Shimizu M, Zaninotto G, Nagata K, Graham DY and Lauwers GY: Esophageal squamous cell carcinoma with special reference to its early stage. Best Pract Res Clin Gastroenterol 27: 171-186, 2013.

4. Conteduca V, Sansonno D, Ingravallo G, Marangi S, Russi S, Lauletta G and Dammacco F: Barrett's esophagus and esophageal cancer: An overview. Int J Oncol 41: 414-424, 2012.

5. Du Z, Ma K, Sun X, et al: Methylation of RASSF1A gene promoter and the correlation with DNMT1 expression that may contribute to esophageal squamous cell carcinoma. World J Surg Oncol 13: 141, 2015.

6. Wang AH, Liu Y, Wang B, et al: Epidemiological studies of esophageal cancer in the era of genome-wide association studies. World J Gastrointest Pathophysiol 5: 335-343, 2014.

7. Ma G, Zhang X, Ma Q, et al: A novel multivariate scoring system for determining the prognosis of lymph node-negative esophageal squamous cell carcinoma following surgical therapy: An observational study. Eur J Surg Oncol 41: 541-547, 2015.

8. Arnold M, Colquhoun A, Cook MB, Ferlay J, Forman D and Soerjomataram I: Obesity and the incidence of upper gastro-intestinal cancers: An ecological approach to examine differences across age and sex. Cancer Epidemiol Biomarkers Prev 25: 90-97, 2016.
9. Thrift AP: The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol 41: 88-95, 2016.
10. Trevellin E, Scarpa M, Carraro A, Lunardi F, Kotsafti A, Porzionato A, Saadeh L, Cagol M, Alfieri R, Tedeschi U, *et al*: Esophageal adenocarcinoma and obesity: Peritumoral adipose tissue plays a role in lymph node invasion. Oncotarget 6: 11203-11215, 2015.
11. Ahrens TD, Werner M and Lassmann S: Epigenetics in esopha-geal cancers. Cell Tissue Res 356: 643-655, 2014.
12. Ushijima T: Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5: 223-231, 2005.
13. Kuo IY, Chang JM, Jiang SS, Chen CH, Chang IS, Sheu BS, Lu PJ, Chang WL, Lai WW and Wang YC: Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients. Int J Med Sci 11: 779-787, 2014.
14. Murata A, Baba Y, Watanabe M, Shigaki H, Miyake K, Ishimoto T, Iwatsuki M, Iwagami S, Yoshida N, Oki E, *et al*: IGF2 DMR0 methylation, loss of imprinting, and patient prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol 21: 1166-1174, 2014.
15. Vasavi M, Ponnala S, Gujjari K, Boddu P, Bharatula RS, Prasad R, Ahuja YR and Hasan Q: DNA methylation in esopha-geal diseases including cancer: Special reference to hMLH1 gene promoter status. Tumori 92: 155-162, 2006.
16. De Oliveira SR, Da Silva IC, Mariz BA, Pereira AM and De Oliveira NF: DNA methylation analysis of cancer-related genes in oral epithelial cells of healthy smokers. Arch Oral Biol 60: 825-833, 2015.
17. Sun MZ, Ju HX, Zhou ZW, Jin H and Zhu R: Single nucleotide polymorphisms of DNA mismatch repair genes MSH2 and MLH1 confer susceptibility to esophageal cancer. Int J Clin Exp Med 7: 2329-2333, 2014.
18. Wang F, Xie XJ, Piao YS, Liu B and Wang LD: Methylation of p16 and hMLH1 genes in esophageal squamous cell carcinoma and reflux esophagitis. Zhonghua Bing Li Xue Za Zhi 40: 537-541, 2011 (In Chinese).
19. Uehara H, Miyamoto M, Kato K, Cho Y, Kurokawa T, Murakami S, Fukunaga A, Ebihara Y, Kaneko H, Hashimoto H, *et al*: Deficiency of hMLH1 and hMSH2 expression is a poor prog-nostic factor in esophageal squamous cell carcinoma. J Surg Oncol 92: 109-115, 2005.
20. Vogelsang M, Wang Y, Veber N, Mwapagha LM and Parker MI: The cumulative effects of polymorphisms in the DNA mismatch repair genes and tobacco smoking in oesophageal cancer risk. PLoS One 7: e36962, 2012.
21. He Y, Xu X, Chen H, Wang J, Xiong W, Xu Y and Liu J: The hMLH1 promoter polymorphisms and cancer susceptibility in Asian populations: A meta-analysis. Gene 523: 199-204, 2013.
22. Li Y, Yang Y, Lu Y, Herman JG, Brock MV, Zhao P and Guo M: Predictive value of CHFR and MLH1 methylation in human gastric cancer. Gastric Cancer 18: 280-287, 2015.
23. Veganzones S, Maestro ML, Rafael S, de la Orden V, Vidaurreta M, Mediero B, Espantaleón M, Cerdán J and Díaz-Rubio E: Combined methylation of p16 and hMLH1 (CMETH2) discriminates a subpopulation with better prognosis in colorectal cancer patients with microsatellite instability tumors. Tumour Biol 36: 3853-3861, 2015.
24. Ling ZQ, Li P, Ge MH, Hu FJ, Fang XH, Dong ZM and Mao WM: Aberrant methylation of different DNA repair genes demonstrates distinct prognostic value for esophageal cancer. Dig Dis Sci 56: 2992-3004, 2011.
25. Baba Y, Watanabe M and Baba H: Review of the alterations in DNA methylation in esophageal squamous cell carcinoma. Surgery Today 43: 1355-1364, 2013.
26. Edge SB and Compton CC: The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474, 2010.
27. Wu D, Xu J, Yu G, Zhang B, Wang H, Wang C, Ru G, Sun A, Shen L and Wei Q: Expression status of fatty acid synthase (FAS) but not HER2 is correlated with the differentiation grade and prognosis of esophageal carcinoma. Hepatogastroenterology 60: 99-106, 2013.
28. Grady WM, Rajput A, Lutterbaugh JD and Markowitz SD: Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 61: 900-902, 2001.
29. Mu L and Mukamal KJ: Alcohol consumption and rates of cancer screening: Is cancer risk overestimated? Cancer Causes Control 27: 281-289, 2016.
30. Organization WH: Guidelines for controlling and monitoring the tobacco epidemic. World Health Organization 119: 63-64, 1998.
31. Tzao C, Hsu HS, Sun GH, Lai HL, Wang YC, Tung HJ, Yu CP, Cheng YL and Lee SC: Promoter methylation of the hMLH1 gene and protein expression of human mutL homolog 1 and human mutS homolog 2 in resected esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 130: 1371, 2005.
32. Rodriguez-Hernàndez I, Garcia JL, Santos-Briz A, Hernández-Laín A, González-Valero JM, Gómez-Moreta JA, Toldos-González O, Cruz JJ, Martin-Vallejo J and González-Sarmiento R: Integrated analysis of mismatch repair system in malignant astrocytomas. PLoS One 8: e76401, 2013.
33. Yang W, Wang X, Li X, Wang M, Chen X, Wu X, Wang Y, Fan Y and Jin H: The specific methylation characteristics of cancer related genes in Chinese colorectal cancer patients. Tumour Biol 35: 8267-8279, 2014.
34. Jin J, Xie L, Xie CH and Zhou YF: Aberrant DNA methylation of MGMT and hMLH1 genes in prediction of gastric cancer. Genet Mol Res 13: 4140-4145, 2014.
35. Su Y, Yin L, Liu R, Sheng J, Yang M, Wang Y, Pan E, Guo W, Pu Y, Zhang J and Liang G: Promoter methylation status of MGMT, hMSH2, and hMLH1 and its relationship to corre-sponding protein expression and TP53 mutations in human esophageal squamous cell carcinoma. Med Oncol 31: 784, 2014.
36. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T and Nephew KP: Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 72: 2197-2205, 2012.
37. Miladi-Abdennadher I, Abdelmaksoud-Damak R, Ayadi L, Khabir A, Frikha F, Kallel L, Frikha M, Sellami-Boudawara T, Gargouri A and Mokdad-Gargouri R: Aberrant methylation of hMLH1 and p16INK4a in Tunisian patients with sporadic colorectal adenocarcinoma. Biosci Rep 31: 257-264, 2011.
38. Sukocheva OA, Wee C, Ansar A, Hussey DJ and Watson DI: Effect of estrogen on growth and apoptosis in esophageal adeno-carcinoma cells. Dis Esophagus 26: 628-635, 2013.
39. Li Y, Liu S, Wang L and Zhou M: Burden of disease attributable to main behavioral risk factor of chronic disease inactivity in China, 1990 and 2010. Zhonghua Yu Fang Yi Xue Za Zhi 49: 333-338, 2015 (In Chinese).
40. Lepage C, Drouillard A, Jouve JL and Faivre J: Epidemiology and risk factors for oesophageal adenocarcinoma. Dig Liver Dis 45: 625-629, 2013.
41. Zheng Y, Cao X, Wen J, Yang H, Luo K, Liu Q, Huang Q, Chen J and Fu J: Smoking affects treatment outcome in patients with resected esophageal squamous cell carcinoma who received chemotherapy. PLoS One 10: e0123246, 2015.
42. Kumagai N, Wakai T, Akazawa K, Ling Y, Wang S, Shan B, Okuhara Y, Hatakeyama Y and Kataoka H: Heavy alcohol intake is a risk factor for esophageal squamous cell carcinoma among middle-aged men: A case-control and simulation study. Mol Clin Oncol 1: 811-816, 2013.
43. Wang CC, Mao WM and Ling ZQ: DNA methylation status of RARβ2 and p16 (INK4α) in peripheral blood and tumor tissue in patients with esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi 34: 441-445, 2012 (In Chinese).